Loading...

Incyte Corporation

INCYNASDAQ
Healthcare
Biotechnology
$70.20
$-0.29(-0.41%)

Incyte Corporation (INCY) Stock Overview

Explore Incyte Corporation’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B+

Score: 72.3/100

Key Financials

Market Cap13.6B
P/E Ratio642.61
EPS (TTM)$0.20
ROE0.01%
Fundamental Analysis

AI Price Forecasts

1 Week$68.18
1 Month$71.27
3 Months$73.23
1 Year Target$66.32

INCY Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Incyte Corporation (INCY) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 58.00, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $66.32.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 642.61 and a market capitalization of 13.6B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Frequently Asked Questions

;